Document is current
Any future updates will be listed below
-
Authors
Sidorenko, Valeria
Scodeller, Pablo
Uustare, Ain
Ogibalov, Ivan
Tasa, Andrus
Tshubrik, Olga
Salumäe, Liis
Sugahara, Kazuki N.
Simón-Gracia, Lorena
Teesalu, Tambet
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (RYC2020-028754-I)
Sihtasutus Archimedes (LMVBS17506, LMVBS17506, LMVBS17506)
European Regional Development Fund (MOBJD11, 2014-2020.4.01.15-0012)
Eesti Teadusagentuur (PRG230)
EuroNanoMed III (ECM-CART)
TRANSCAN3 (ReachGLIO)
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 11 June 2024
First Online: 30 July 2024
Competing interests
: TT and KNS are inventors of patents on CendR peptides and shareholders of Lisata Therapeutics, a company that develops iRGD peptide for cancer therapy. VS, LSG, OT, AT, AU, IO, and TT are inventors of patent application for Utorubicin (application TD 40725/ST). PS and LS have no conflict of interest.
